The Tumor Suppressor p53 Down-Regulates Glucose Transporters GLUT1 and GLUT4 Gene Expression

Cancer Research

Volumn 64, Issue 7, 2004, Pages 2627-2633

  Schwartzenberg Bar Yoseph, Fabiana ^a   Armoni, Michai ^a   Karnieli, Eddy ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; PROTEIN P43;

ARTICLE; CANCER CELL CULTURE; DNA PROBE; DNA PROTEIN COMPLEX; GENE EXPRESSION REGULATION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; MUTAGENESIS; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROMOTER REGION; TUMOR SUPPRESSOR GENE;

ANIMALS; BASE SEQUENCE; BONE NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORTER TYPE 1; GLUCOSE TRANSPORTER TYPE 4; HUMANS; MICE; MOLECULAR SEQUENCE DATA; MONOSACCHARIDE TRANSPORT PROTEINS; MUSCLE PROTEINS; MUSCLE, SKELETAL; OSTEOSARCOMA; POINT MUTATION; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; RHABDOMYOSARCOMA, EMBRYONAL; TRANS-ACTIVATION (GENETICS); TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 1942506067     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-0846     Document Type: Article

References (45)

1. Hollingsworth RE, Lee WH. Tumor suppressor genes: new prospects for cancer research. J Natl Cancer Inst (Bethesda) 1991;83:91-6.
2. Hatanaka M. Transport of sugars in tumor cell membranes. Biochim Biophys Acta 1974;355:77-104.
3. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987;235:1492-5.
4. Oren M, Damalas A, Gottlieb T, Michael D, Taplick J, Leal JF, et al. Regulation of p53: intricate loops and delicate balances. Biochem Pharmacol 2002;64:865-71.
5. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
6. Oren M. Regulation of the p53 tumor suppressor protein. J Biol Chem 1999;274:36031-4.
7. Lane DP, Lain S. Therapeutic exploitation of the p53 pathway. Trends Mol Med 2002;8:S38-42.
8. Hollstein M, Hergenhahn M, Yang Q, Bartsch H, Wang ZQ, Hainaut P. New approaches to understanding p53 gene tumor mutation spectra. Mutat Res 1999;431:199-209.
9. Kahn BB, Facilitative glucose transporters: regulatory mechanisms and dysregulation in diabetes. J Clin Investig, 1992;89:1367-74.
10. MacDougald OA, Lane MD. Transcriptional regulation of gene expression during adipocyte differentiation. Annu Rev Biochem 1995;64:345-73.
11. Maor G, Karnieli E. The insulin-sensitive glucose transporter (GLUT4) is involved in early bone growth in control and diabetic mice, but is regulated through the insulin-like growth factor 1 receptor. Endocrinology 1999;140:1841-51.
12. Werner H, Hernandez-Sanchez C, Karnieli E, Leroith D. The regulation of IGF-1 receptor gene expression. Int J Biochem Cell Biol 1995;27:987-94.
13. Younes M, Brown RW, Mody DR, Fernandez L, Laucirica R. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res 1995;15:2895-8.
14. Haber RS, Weiser KR, Pritsker A, Reder I, Burstein DE. GLUT1 glucose transporter expression in benign and malignant thyroid nodules. Thyroid 1997;7:363-7.
15. Yamamoto T, Seino Y, Fukumoto H, et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 1990;170:223-30.
16. Kurata T, Oguri T, Isobe T, Ishioka S, Yamakido M. Differential expression of facilitative glucose transporter (GLUT) genes in primary lung cancers and their liver metastases. Jpn J Cancer Res 1999;90:1238-43.
17. Medina RA, Owen GI. Glucose transporters: expression, regulation and cancer. Biol Res 2002;35:9-26.
18. Nagamatsu S, Sawa H, Wakizaka A, Hoshino T. Expression of facilitative glucose transporter isoforms in human brain tumors. J Neurochem 1993;61:2048-53.
19. Ito T, Noguchi Y, Satoh S, Hayashi H, Inayama Y, Kitamura H. Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. Mod Pathol 1998;11:437-43.
20. Noguchi Y, Marat D, Saito A, Yoshikawa T, Doi C, Fukuzawa K, et al. Expression of facilitative glucose transporters in gastric tumors. Hepatogastroenterology 1999;46:2683-9.
21. Armoni M, Quon MJ, Maor G, Avigad S, Shapiro DN, Harel C, et al. PAX3/forkhead homolog in rhabdomyosarcoma oncoprotein activates glucose transporter 4 gene expression in vivo and in vitro. J Clin Endocrinol Metab 2002;87:5312-24.
22. Berlangieri SU, Scott AM. Metabolic staging of lung cancer. N Engl J Med 2000;343:290-2.
23. Webster NJ, Resnik JL, Reichart DB, Strauss B, Haas M, Seely BL. Repression of the insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer. Cancer Res 1996;56:2781-8.
24. Werner H, Karnieli E, Rauscher FJ, LeRoith D. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor 1 receptor gene. Proc Natl Acad Sci USA 1996;93:8318-23.
25. Fogh J, Wright WC, Loveless JD. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst (Bethesda) 1977;58:209-14.
26. Felix CA, Kappel CC, Mitsudomi T, Nau MM, Tsokos M, Crouch GD, et al. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res 1992;52:2243-7.
27. Quon MJ, Zarnowski MJ, Guerre-Millo M, de la Luz Sierra M, Taylor SI, Cushman SW. Transfection of DNA into isolated rat adipose cells by electroporation: evaluation of promoter activity in transfected adipose cells which are highly responsive to insulin after one day in culture. Biochem Biophys Res Commun 1993;194:338-46.
28. Armoni M, Kritz N, Harel C, Bar-Yoseph F, Quon MJ, and Kamieli E. Peroxisome proliferator-activated receptor γ represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect. J Biol Chem 2003;278:30614-23.
29. Lee Y, Chen Y, Chang LS, Johnson LF. Inhibition of mouse thymidylate synthase promoter activity by the wild-type p53 tumor suppressor protein. Exp Cell Res 1997;234:270-6.
30. Sambrook J. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989.
31. Zambetti G, Levine A. A comparison of the biological activities of wild-type and mutant p53. FASEB J 1993;7:855-65.
32. Blagosklonny M. Loss of function and p53 protein stabilization. Oncogene 1997;15:1889-93.
33. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992;1:45-9.
34. Shiio Y, Yamamoto T, Yamaguchi N. Negative regulation of Rb expression by the p53 gene product. Proc Natl Acad Sci USA 1992;89:5206-10.
35. Miyashita T, Harigai M, Hanada M, Reed J. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994;54:3131-5.
36. Wang Q, Zambetti G, Suttle D. Inhibition of DNA topoisomerase II α gene expression by the p53 tumor suppressor. Mol Cell Biol 1997;17:389-97.
37. Seto E, Usheva A, Zambetti G, Momand J, Horikoshi N, Weinmann R, et al. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci USA 1992;89:12020-32.
38. Liu X, Berk A. Reversal of in vitro p53 squelching by both TFIIB and TFIID. Mol Cell Biol 1995;15:6474-8.
39. Horikoshi N, Usheva A, Chen J, Levine A, Weinmann R, Shenk T. Two domains of p53 interact with the TATA-binding protein, and the adenovirus 13S E1A protein disrupts the association, relieving p53-mediated transcriptional repression. Mol Cell Biol 1995;15:227-34.
40. Bell GI, Kayano T, Buse JB, Burant CF, Takeda J, Lin D, et al. Molecular biology of mammalian glucose transporters. Diabetes Care 1990;13:198-208.
41. Yamaguchi A, Tamatani M, Matsuzaki H, Namikawa K, Kiyama H, Vitek MP, et al. Akt activation protects hippocampal neurons from apoptosis by inhibiting transcriptional activity of p53. J Biol Chem 2001;276:5256-64.
42. Budhram-Mahadeo V, Morris PJ, Smith MD, Midgley CA, Boxer LM, Latchman DS. p53 suppresses the activation of the Bcl-2 promoter by the Brn-3a POU family transcription factor. J Biol Chem 1999;274:15237-44.
43. Lee KC, Crowe AJ, Barton MC. p53-mediated repression of α-fetoprotein gene expression by specific DNA binding. Mol Cell Biol 1999;19:1279-88.
44. Ori A, Zauberman A, Doitsh G, Paran N, Oren M, Shaul Y. p53 binds and represses the HBV enhancer: an adjacent enhancer element can reverse the transcription effect of p53. EMBO J 1998;17:544-53.
45. Johnson RA, Ince TA, Scotto KW. Transcriptional repression by p53 through direct binding to a novel DNA element. J Biol Chem 2001;276:27716-20.